Our study demonstrated that IFITM3 upregulates MHC-I expression and enhances tumor sensitivity to PD-1 inhibitors in SCLC patients by promoting CD8 + T cell infiltration and cytotoxic. Here, CD8A is linked to small cell lung carcinoma.